Seastar’s selective cytopheretic device (SCD) has improved the clinical status of four critically ill paediatric and adult patients across multiple clinical conditions. Credit: Irin Somsuppamongkol via Getty Images.

Seastar has released positive case studies showing that its selective cytopheretic device (SCD) improved the clinical status of four critically ill paediatric and adult patients across multiple clinical conditions. 

The SCD is designed to modulate the immune response in critically ill patients undergoing continuous kidney renal therapy (CKRT). The device selectively targets and removes pro-inflammatory neutrophils and monocytes from the blood, reducing excessive inflammation and the cytokine storm that can lead to organ failure and death. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The manuscript highlights four case studies in which critically ill paediatric and adult patients with multiorgan failure who were treated with its SCD successfully stabilised and improved their clinical status prior to stem cell or liver transplant or left ventricular assist device implantation. 

Patients need to be in a relatively stable and healthy condition before they can receive a transplant or artificial organ. If a patient has too much inflammation in their body, it can prevent their immune system from stabilising and their organs from healing. 

The SCD has breakthrough device designation from the US Food and Drug Administration (FDA) for adults with acute kidney injury (AKI), cardiorenal syndrome and hepatorenal syndrome. In January 2023, SeaStar Medical entered a US licence and distribution agreement with Nuwellis for SCD in acute kidney injury (AKI). 

In June 2023, the US-based company fixed supply chain issues that impacted the sourcing of the tubing connector components of the SCD. Following this, the company began enrolling patients into the NEUTRALIZE-AKI trial (NCT05758077) which is evaluating whether up to ten 24-hour treatments with the SCD will improve survival in AKI patients who need CKRT when compared to CKRT alone. The estimated completion date of the study is in 2025. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In February 2024, Seastar received FDA approval under a Humanitarian Device Exemption for use in children weighing 10kg or more with AKI and sepsis. Children with a septic condition requiring continuous CKRT anytime within the next 30 to 45 days will also be indicated. 

Seastar’s medical CEO Eric Schrolff said: “This clinical development strategy is expected to pave the way for market approvals for a therapeutic device that we believe can improve the quality of life for severely ill patients and help save lives.”